All News
”As the content experts in immunology, our knowledge and insights are relevant... We [Rheumatologists] should always be in the room that such discussions [about patient care and development of vaccines] happen. “ - Dr. Ellen Gravallese, ACR President #ACR20 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Thank you to the ACR Executive Committee for all your hard work and efforts. And thank you Dr. Gravallese for an amazing start to the #ACR20 and your great leadership. @RheumNow https://t.co/eRrXo21v0Y
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Congratulations, Dr. James O’Dell on the ACR’s highest reward: the President Gold Medal. I had the privilege of meeting him years ago— such an exemplary person, physician, and leader. #ACR20 @RheumNow https://t.co/4R23itqGZJ
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Infectious disease physician, Dr. Eric Rubin, kicks off the ACR keynote address by reminding us that there are real alliances between Infectious Disease doctors and Rheumatologists in that inflammation can cause damage during infection! #ACR20 @RheumNow https://t.co/pcOS1HbfX7
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Reminder of the glucocorticoids (GC) paradigm: don’t use them early during viral replication as morbidity and mortality (M&M) can increase with early use! But GCs CAN prevent the late complications that cause M&M when used at the appropriate time point. #ACR20 @RheumNow https://t.co/l2e0J1nANd
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Determining safety of a vaccine requires NUMBERS (more subjects to detect rare, serious side effects) and TIME (longer trials to be able to detect more delayed side effects) per Dr. Eric Rubin’s (ID physician’s) keynote address at #ACR20 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Perform (annual) skin exams in patients in MTX based on discovery of a new adverse effect signal with use of low dose MTX (median dose 15 mg/wk) with a NNH of 167! Screening 160 RA patients on MTX will identify 1 skin Ca. Amazing #ACR20 Year in Review by @JYazdanyMD. @RheumNow https://t.co/hUCzKSYZnB
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
*When will we have a vaccine?
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
“When we will have a vaccine. The answer is not so simple. Safety [of vaccines] is an important component of making a decision to move forward.”- Dr. Eric Rubin at #ACR20.
We want a vaccine that is both SAFE and EFFECTIVE! @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Abst#0142 at #ACR20, a post-hoc analysis of FINCH2, shows that filgotinib (FIL)(Jak1-i) + csDMARD improved the degree of activity impairment in a clinically relevant manner compared to placebo + csDMARD in pts w/ inadequate response to bDMARD . @RheumNow https://t.co/6M42LUVuht
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Great #rheumtwearls #ACR20 https://t.co/HzKkhnArvr
Marissa Blum blum_marissa ( View Tweet)
ACPA in patients with RA are multireactive. How can one antibody bind to so many proteins? ACPA recognize very small linear epitopes shared by many posttranslationally modified proteins.
2F012. Antibodies in RA. #ACR20. <TK https://t.co/OUqshFoxSb
ARD & RMD Open ARD_BMJ ( View Tweet)
Year in review @JYazdanyMD take home points from 2 key positive trials (finally!) in SLE this year #ACR20 @RheumNow https://t.co/74SVwNavPK
Richard Conway RichardPAConway ( View Tweet)
#ACR20 Year in Review @JYazdanyMD presenting PEXIVAS results. The proof of efficacy equivalence and safety superiority for the low dose steroid arm is a game-changer @rheumnow https://t.co/bJ1WLL71sB
Richard Conway RichardPAConway ( View Tweet)
Who will be more likely to have chronic reactive arthritis @RheumNow #ACR20 @CRASCRRheum
Janet Pope Janetbirdope ( View Tweet)
IL-6 blockade for management of irAEs without inhibiting anti cancer immune response. Should these be given prior or concomitantly with ICIs? Some interesting ideas to look up from the cancer and immunotherapy study group. #ACR20 @UTSWNews @ACRheum @RheumNow
Adela Castro AdelaCastro222 ( View Tweet)
#ACR20 Abstr#0433 #PlenaryACR Georgia SLE registry 336 pts ⬆️stroke/isch heart dz with:
👉3X stroke risk and 24X IHD risk for black pts
👉predictors stroke: black race, DLE, renal dz
👉predictors IHD: age>65, black race, neuro & immuno d/o (e.g, APAs)
@RheumNow https://t.co/u6Ky7r0FYF
k dao KDAO2011 ( View Tweet)
Plenary session 1 no#2F011 #ACR20 @rheumnow
Black #SLE patients have a 3 fold higher stroke and 24 fold higher Ishemic Heart Disease risk! https://t.co/AYtiXk7pDa
Bella Mehta bella_mehta ( View Tweet)
Tech support during #ACR 20 per below if needed! @RheumNow https://t.co/6OIvJDJReq
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Environmental and geographical factors matter! @rheumnow #ACR20 https://t.co/uq8236Dv5r
Bella Mehta bella_mehta ( View Tweet)